AI drug discovery growth and guidance

Q: Subhalaxmi Nambi of Guggenheim asked why growth appears to be moderating for AI drug discovery and how much of the revenue is in the backlog.

A: CEO Emily Leproust responded that growth is actually accelerating, noting revenue growth moved from 17% to 28% in the fourth quarter. She expressed confidence in achieving triple-digit percentage order growth in fiscal 2027 and noted that while the initial guidance is $100 million, there is meaningful upside potential.

Q: Steven Etoch of Stephens asked about the underlying characteristics of the DNA synthesis and protein solutions market given the AI expectations.

A: CEO Emily Leproust explained that the science is working, with customers moving from model building to true drug discovery programs. She noted that demand for pooled discovery is increasing and that more traditional drug discovery companies are adopting AI approaches.

Revenue drivers and growth breakdown

Q: Douglas Schenkel of UBS asked what drives the $100 million revenue growth in fiscal 2027 outside of the AI drug discovery contribution.

A: CFO Adam Laponis stated that NGS applications are growing above 20% and therapeutics are growing well. He added that the company expects to see double-digit growth for the rest of the business outside of AI drug discovery.

AI revenue disclosure and upside

Q: Vijay Kumar of Evercore asked if the company still expects triple-digit AI order growth and how they will disclose AI numbers going forward.

A: CEO Emily Leproust stated the company is committed to transparency while protecting competitive information. She noted that upside comes from finding more customers, launching new workflows like cell-free, and faster turnaround times.

Order dynamics and capacity expansion

Q: Puneet Souda of Leerink asked if there is a dynamic between orders and revenue conversion and what triple-digit order growth implies.

A: CEO Emily Leproust clarified there is no negative dynamic between orders and revenue and confirmed that triple-digit growth means growth significantly above 100%. She reiterated confidence in delivering this growth in fiscal 2027.

Q: Matthew Larew of William Blair asked about the mix of expanded scale versus new capabilities in capital expenditures.

A: President and COO Patrick Finn noted the company is increasing DNA writer capacity from 32 million nucleotides per day to more than 50 million. He emphasized that capital deployment is balanced and disciplined to meet customer demand.

MRD and NGS growth

Q: Matt Stanton of Jefferies asked how to think about the ability for MRD to accelerate in fiscal 2027.

A: CFO Adam Laponis explained that while it is early days for commercial adoption, dollar growth is expanding. He does not expect the percentage growth rate to slow as the company moves into 2027.

DNA synthesis and protein mix

Q: David Westenberg of Piper Sandler asked how the mix of AI versus traditional customers is reflected in DNA synthesis and protein solutions.

A: CEO Emily Leproust explained that gene volume is growing faster than revenue because of a mix shift toward antibodies, which use smaller genes. She reiterated that the company focuses on revenue growth and profitability rather than specific customer categorization.

Long-term AI outlook and mRNA

Q: Kyle Mikson of Canaccord Genuity asked about the long-term AI revenue tail and the risk of companies building their own labs.

A: CEO Emily Leproust stated the science is broad-based and long-lasting. She added that even if customers build their own labs, they will still require the company's DNA and protein products.

Q: Luke Sergott of Barclays asked if AI upside is contingent on capacity and about the mRNA opportunity.

A: CEO Emily Leproust confirmed that capacity is being added weekly. She described mRNA as a longer-term opportunity where the company is currently servicing clinical trials.

Gross margins and incremental conversion

Q: Robert Bamberger of Baird asked how to bridge to the 75% to 80% incremental gross profit framework.

A: CFO Adam Laponis confirmed the 75% to 80% framework still holds. He noted that 2027 investments in capacity and automation create a 2 to 3 point headwind from depreciation, but the company maintains a path to 60% gross margin in the future.

Customer base expansion

Q: Brendan Smith of TD Cowen asked how many customers are in the AI data orders bucket and if the base is expanding.

A: CFO Adam Laponis confirmed the customer group is expanding and includes big pharma, native AI discovery companies, and hyperscalers. He noted the base has expanded sequentially almost every quarter.